Document is current
Any future updates will be listed below
-
Authors
Levin, Myron J.
Ustianowski, Andrew
De Wit, Stephane
Beavon, Rohini
Thissen, Jesse
Seegobin, Seth
Dey, Kanika
Near, Karen A.
Streicher, Katie
Kiazand, Alexandre
Esser, Mark T.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04625725 at ClinicalTrials.govnct04625972 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
https://doi.org/10.1007/s40121-024-00970-x
4CPS-096 Use of covid-19 antivirals in patients previously treated with tixagevimab/cilgavimab prophylaxis: experience of an Italian hospital
https://doi.org/10.1136/ejhpharm-2024-eahp.200
Documents that mention this clinical trial
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
https://doi.org/10.1007/s40121-024-00970-x
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 11 December 2023
Accepted: 28 March 2024
First Online: 4 May 2024
Declarations
:
: Myron J. Levin reports research support from Johnson & Johnson, Novavax, Moderna, and GSK; consultancy for Merck & Co., GSK, Pfizer, Dynavax and Seqirus; and data safety monitoring/advisory board for GSK. Andrew Ustianowski reports honoraria/speaker fees from AstraZeneca, Sanofi, Merck, Janssen, GSK, and Gilead, and advisory boards for Gilead, Merck, Pfizer, and ViiV Healthcare/GSK. Stephane De Wit reports financial support from AstraZeneca for the conduct of this study. Myron J. Levin, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie Streicher, Alexandre Klazand, and Mark T. Esser are employees of, and may hold stock and/or stock options in, AstraZeneca.
: These studies adhered to Good Clinical Practice guidelines and the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical guidelines, applicable International Conference on Harmonisation Good Clinical Practice guidelines, and all applicable laws and regulations. The protocols were approved by the institutional review boards of the coordinating centers for PROVENT (WIRB Copernicus) and STORM CHASER (Advarra IRB) as well as the institutional review boards or ethics committees at all other participating centers (Supplementary Table ). All participants provided informed, written consent.
